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Background: The relationship between optimization according to left ventricular (LV) dp/
dt, changes in LV performance, and prognosis of heart failure patients who undergo cardiac
resynchronization therapy (CRT) remains unclear.
Methods: We studied 27 consecutive patients who underwent CRT implantation (18 males,
9 females; age, 67:3 8:3 years). We measured LV dp/dt to determine the timing of LV-right
ventricular (RV) sequential pacing. Echocardiographic examination was performed before
and after the CRT procedure to assess LV ejection fraction (LVEF) and LV end-diastolic
diameter (LVEDD). Primary endpoints were all-cause death and cardiac hospitalization.
Results: An increase in LV dp/dt during CRT was signiﬁcantly associated with an increase
in LVEF (r ¼ 0:47, p ¼ 0:018), but was not associated with a decrease in LVEDD. The mean
follow-up period was 14 13 months, and six endpoints were observed. In the control group,
no subjects encountered any of the endpoints, and they had higher LVEDD reductions
(5:7 8:4 vs. 2:5 4:6mm; p ¼ 0:034) than those in the event group. Cox regression
analysis revealed that a reduction in LVEDD was a signiﬁcant predictor of event-free survival.
Conclusions: The measurement of LV dp/dt might be useful for the optimization of CRT.
Reductions in LVEDD are necessary to achieve improvements in the long-term prognosis of
CRT patients.
(J Arrhythmia 2011; 27: 208–213)
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Introduction
Cardiac resynchronization therapy (CRT) has
been demonstrated to be beneﬁcial for medically
refractory heart failure patients with cardiac dyssyn-
chrony.1–5) However, approximately 30% of patients
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have been reported as non-responders to CRT.6–9)
The optimization of both atrioventricular (AV) delay
and interventricular (VV) delay is needed to improve
left ventricular (LV) performance; several invasive
as well as noninvasive methods for optimization
have been reported to date.10–18)
Optimization by measurement of LV dp/dt is
invasive, but can be achieved during the CRT
procedure. Some studies of optimization by LV
dp/dt16–18) have been reported; however, the rela-
tionship between optimization by LV dp/dt meas-
urement, changes in LV performance, and middle-to-
long-term prognosis remains unclear.
The aim of this study was to evaluate the
relationship between optimization according to the
measurement of LV dp/dt, changes in LV perform-
ance, and the middle-to-long-term prognosis of
patients with heart failure who undergo CRT.
Patients and Methods
Study population
We examined 27 consecutive patients who under-
went CRT implantation (18 males, 9 females; age
67:3 8:3 years). All patients had medically refrac-
tory heart failure with cardiac dyssynchrony, and all
had appropriate indications for CRT in accordance
with the guidelines of The Japanese Circulation
Society.
Catheterization and stimulation protocol
Hemodynamic measurements were taken using
a 4 Fr pigtail catheter during CRT implantation. The
catheter was advanced into the LV via the right
femoral artery, and LV dp/dt and systolic blood
pressure (SBP) were calculated in real time using a
digital ﬁlter. After placement of the pigtail catheter,
the heart was stimulated. The protocol included
single RV, LV, and biventricular (BiV) stimulation
with either simultaneous (BiV0) or sequential pacing
(LV pre-excitation 20, 40, 60, and 80ms, RV pre-
excitation 20 and 40ms). The optimal VV delay was
determined by the maximum LV dp/dt. We com-
pared the dp/dt and SBP values at baseline (de novo
cases: sinus rhythm; upgrade cases: RV pacing) with
those at optimal VV delay.
Echocardiographic, electrocardiographic, and X-
ray assessment and follow-up protocol
Echocardiographic examination, electrocardiogra-
phy and chest X-ray were performed before and 1
week after the CRT procedure. The LV ejection
fraction (LVEF) was assessed by Simpson’s equa-
tion using apical four-chamber and two-chamber
views,19) and LV end-diastolic diameter (LVEDD)
and LV end-systolic diameter (LVESD) was eval-
uated by the long-axis view. We assessed the QRS
duration, atrial ﬁbrillation, and left bundle branch
block in electrocardiography. The cardiothoracic
ratio was calculated as a percentage of the maximal
horizontal length of a cardiac shadow against that of
bilateral lung ﬁelds on chest X-ray. The primary
endpoint was deﬁned as all-cause mortality and
cardiac hospitalization. The determination that a
primary endpoint had occurred was made after
review of the patient’s medical records by cardiol-
ogists. No patient was lost to follow-up. We deﬁned
the event group as those who suﬀered an event
categorized as a primary endpoint, and the control
group included subjects who had not suﬀered such
an event.
Statistical analysis
All data are expressed as the mean SD or
a percentage. An unpaired t-test and the 2 test
were used for comparison of the mean values and
parameters between the event and control groups.
A paired t-test was used to analyze changes in
LVEF and LVEDD. Cumulative incidences of
primary endpoints were plotted as Kaplan-Meier
curves, and the diﬀerences were assessed using
the log-rank test. In the multiple logistic regres-
sion model for endpoints, we adjusted for age
and gender. All statistical analyses were per-
formed using the computer software package
SPSS, version 15.0J (SPSS Inc., Chicago, IL). A
probability value of <0:05 was considered as
statistically signiﬁcant.
Results
The baseline characteristics are shown in Table 1.
The underlying cardiac diseases were dilated cardio-
myopathy (11 cases), ischemic heart disease (5
cases), sarcoidosis (5 cases), hypertrophic cardio-
myopathy (3 cases), hypertensive heart disease (2
cases), and valvular disease (1 case).
The LV dp/dt was 896 246mmHg/s and the
SBP was 102 21mmHg before CRT, and the LV
dP/dt was 1;112 312mmHg/s and the SBP was
107 23mmHg according to optimal VV delay. We
optimized CRT as follows: LV pre-excitation pacing
was set in 19 patients, BiV pacing (LV and RV VV
interval = 0ms) in 6 patients, and RV pre-excitation
pacing in 2 patients. The total subject analysis
showed increased LVEF (26:7 10:8! 35:6
12:1%; p < 0:001) and decreased LVEDD (67:2
10:2! 63:5 9:2mm; p ¼ 0:042) after CRT
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(Figure 1). An increase in LV dp/dt during CRT was
signiﬁcantly and positively associated with an
increase in LVEF (r ¼ 0:47, p ¼ 0:018), but was
not associated with a decrease in LVEDD (r ¼ 0:05,
p ¼ 0:81) (Figure 2). An increase in SBP during CRT
was not associated with an increase in LVEF
(r ¼ 0:36, p ¼ 0:16) or with a decrease in LVEDD
(r ¼ 0:09, p ¼ 0:73). An increase in LV dp/dt
was not associated with a paced QRS duration
(r ¼ 0:23, p ¼ 0:26).
The mean follow-up period was 14 13 months,
and six endpoints were observed. Five patients were
admitted to the hospital due to heart failure, and one
patient died due to heart failure. Comparison of
event and control groups is shown in Table 2. In
the control group, no subjects suﬀered an endpoint,
and this group showed a higher reduction in
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Figure 1 Changes in left ventricular ejection fraction
(LVEF) and left ventricular end-diastolic diameter (LVEDD)
before and after CRT.
Table 1 Patient characteristics
N 27
Age (years) 67:3 8:3
Gender (M/F) 18/9
CRT D/P 24/3
LVEF (%) 26:7 10:8
LVEDD (mm) 67:2 10:2
LVESD (mm) 57:4 12:2
CRT D/P: cardiac resynchronization therapy with deﬁb-
rillator/pacemaker, LVEDD: left ventricular end-diastolic
diameter, LVEF: left ventricular ejection fraction,
LVESD: left ventricular end-systolic diameter
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Figure 2
(A) Association between an increase in left ventricular (LV) dp/dt
(dp/dt) and an increase in left ventricular ejection fraction
(LVEF) (EF change%). (B) Association between an increase in
LV dp/dt (dp/dt) and a decrease in left ventricular end-diastolic
diameter (LVEDD) (EDD). An increase of dp/dt was signiﬁ-
cantly associated with an increase in LVEF, but not with a
decrease in LVEDD.
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LVEDD (5:7 8:4 vs. 2:5 4:6mm; p ¼ 0:034)
than those in the event group; however, the com-
parative increases in dp/dt (26 24 vs. 18 12%,
p ¼ 0:44), maximum dp/dt (1;173 326 vs.
1;082 289mmHg/s, p ¼ 0:32), and changes in
LVEF (49 50% vs. 25 39%; p ¼ 0:31) did not
reach statistical signiﬁcance (Table 2). Cox regres-
sion analysis revealed that a reduction in LVEDD
was a signiﬁcant predictor of endpoint (odds ratio:
0.80, 95% conﬁdence interval 0.63–0.996, Table 3).
The cardiothoracic ratio was reduced in the control
group (60:1 5:7! 59:0 6:0%, p ¼ 0:044), but
it was not changed in the event group (62:2 6:7!
62:5 6:5%, p ¼ 0:75). In patients with sinus
rhythm (N ¼ 22), QRS duration and a decrease of
QRS duration after CRT implantation were similar
in the event group and the control group (QRS
duration: 183 23 vs. 182 40ms, p ¼ 0:96; a
decrease of QRS duration: 13 25 vs. 8 32ms,
p ¼ 0:82).
We divided all subjects into two groups according
to the median LVEDD reduction (3mm), and the
group showing greater reduction experienced fewer
endpoints (Log rank = 4.64, p ¼ 0:031; Figure 3,
Panel A). We also divided the subjects into two
groups according to the median increase in LV
dp/dt (20%), the diﬀerence between endpoints in
each group was not signiﬁcant (Log rank = 0.95,
p ¼ 0:33; Figure 3, Panel B).
Table 2 Comparison of Event and Control groups
Event group
N ¼ 6
Control group
N ¼ 21 p
Age (years) 71 5 66 9 0.26
Gender male (%) 67 62 0.84
BNP (pg/mL) 1;063 106 827 615 0.52
Arial ﬁbrillation (%) 33 14 0.31
LBBB (%) 17 33 0.45
QRS duration (msec) 183 33 175 42 0.69
dp/dt (%) 18 12 26 24 0.44
Maximum dp/dt
(mmHg/s) 1;082 289 1;173 326 0.32
SBP (mmHg) 3:5 7:2 5:2 7:1 0.68
EF (change%) 25 39 49 50 0.31
EDD (decrease [mm]) 2:5 4:6 5:7 8:4 0.034
ESD (decrease [mm]) 0:2 6:8 4:7 6:0 0.12
BNP: brain natriuretic peptide, CRT: cardiac resynchroni-
zation therapy, EDD: decrease of left ventricular end-
diastolic diameter, EF: increase of left ventricular
ejection fraction, ESD: decrease of left ventricular end-
systolic diameter, SBP: increase of systolic blood
pressure, LBBB: left bundle branch block
Table 3 Predictors of cardiovascular events
Odds ratio (95% CI) p
Age (per 1 year) 1.04 (0.92–1.18) 0.50
Gender: male 1.40 (0.22–8.87) 0.72
EDD (per 1-mm decrease) 0.80 (0.63–0.996) 0.047
EDD: decrease in left ventricular end-diastolic diameter
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Figure 3
(A) Kaplan-Meier curve showing cumulative event-free survival
stratiﬁed by the median value of left ventricular end-diastolic
diameter (LVEDD) reduction, (B) Kaplan-Meier curve showing
cumulative event-free survival stratiﬁed by the median value of
increase in left ventricular (LV) dp/dt. Patients with an LVEDD
reduction above the median value showed a higher rate of event-
free survival. On the other hand, patients with an increase in left
ventricular (LV) dp/dt that was above or below the median
showed similar rates of event-free survival.
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Discussion
The two main ﬁndings of this study were that
increases in LV dp/dt were associated with increases
in LVEF, and that decreases in LVEDD were
predictive of event-free survival.
Inter-ventricular delay caused a shortening of LV
diastolic ﬁlling time, an increase in mitral regurgi-
tation, and a decrease in LV dp/dt; in general, a
worsening of hemodynamic status was seen among
heart failure patients.20) It has been shown that an
improvement in dyssynchrony causes increased LV
dp/dt.16–18) Doppler-derived LV dp/dt is known to
be related to the degree of LV dyssynchrony, and the
dp/dt calculated during the early phases of systole
during isovolumic contraction played a role as a
mechanism of the relationship between LV dp/dt
and the degree of LV dyssynchrony.21) In this study,
we demonstrated that LV dp/dt and SBP had
increased after CRT, and that increases in dp/dt
were associated with increases in LVEF. Therefore,
the optimization of VV delay by measurement of
the LV dp/dt results enhanced increases in the
LVEF. Thus, this approach might be useful for
improving the prognosis of heart failure patients
who undergo CRT. The optimization of VV delay is
particularly important in nonresponders who under-
go an optimization of AV delay to reduce cardiac
preload;16) it appears likely that the optimization of
VV delay by LV dp/dt may have contributed, in
these cases, to an increase in the rate of responders to
CRT.
The LVEF, LVESD, and LVEDD are used as
parameters of improvement in cardiac function. A
decrease in LVEDD was viewed as a predictor of
event-free survival in this study. It has been shown
that decreases in LV diameter are associated with
cardiovascular events and mortality.22) When only
the optimization of VV delay was addressed, LV
reverse remodeling by CRT was found to be
insuﬃcient.23) Therefore, the optimization of AV
delay is also necessary to achieve suﬃcient LV
reverse remodeling. Optimal pharmacotherapy is
also important for improving the prognosis of heart
failure patients who have undergone CRT.24) Al-
though heart failure management should include
the utilization of evidence-based treatment, optimal
pharmacological treatment is not administered in
most cases.25) Auricchio et al. demonstrated that
LV end-diastolic pressure did not diﬀer among
responders and nonresponders in the acute phase of
disease.16) Within a relatively short observational
period, optimization by VV delay did not yield a
suﬃcient reduction in LV diameter, even among
responders. In this study, a reduction in LVEDD 1
week after CRT implantation was the best predictor
of event-free survival. The cardiothoracic ratio might
be a useful parameter in the same capacity.
LV dp/dt was associated with increases in LVEF,
but an increase of LV dp/dt was not associated with
event-free survival. Two explanations for this dis-
crepancy might be considered. First, reverse remod-
eling in the chronic phase might not be associated
with an increase of LV dp/dt, and the increase of
LVEF, which was assessed by echocardiographic
examination 1 week after the CRT procedure, may
not have been suﬃcient to predict long-term prog-
nosis. And second, the absolute value of LV dp/dt,
but not an increase of dp/dt, might have been
associated with prognosis. In this study, although
maximum LV dp/dt did not diﬀer signiﬁcantly in the
case and control group, further studies including
larger numbers of subjects will be needed to clarify
the association between the absolute value of LV
dp/dt after CRT implantation and long-term prog-
nosis.
This study included some limitations. First, the
sample size was relatively small and there was no
long-term follow-up. Second, we did not obtain
enough echocardiographic examination data over the
follow-up period. These factors might have aﬀected
the discrepancy between the increase of LVEF and
clinical outcomes regarding CRT optimization using
dp/dt. We could not obtain and assess data on the
6-min walking distance, which was used as an index
of responders to CRT. Future studies including a
larger sample and index of quality of life will be
needed to clarify the relationship between increased
LV dp/dt and long-term prognosis.
Conclusions
Changes in LV dp/dt might be useful for
optimizing CRT. Amelioration of clinical symptoms,
reﬂected by a reduction in LVEDD, is needed to
achieve an improvement in the long-term prognosis
of CRT patients.
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